Inhibace (Cilazapril)

Cilazapril blocks the angiotensin‑converting enzyme, which stops the formation of angiotensin II, a powerful vasoconstrictor. The resulting vasodilation lowers peripheral resistance, reduces aldosterone‑mediated sodium retention, and ultimately decreases blood pressure while easing the workload on the heart.

The appropriate dose of Inhibace is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, severity of heart failure, kidney function, and other concurrent medications. Dosage adjustments are made during follow‑up visits to achieve therapeutic goals while minimizing side effects.

The safety of cilazapril in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative therapies with their healthcare provider.

To request Inhibace, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Cilazapril shares the core mechanism of ACE inhibition with other agents in its class, offering comparable blood‑pressure reduction and heart‑failure benefits. Differences may lie in pharmacokinetic profiles, dosing frequency, and individual tolerability; clinicians choose the specific ACE inhibitor based on patient response and safety considerations.

Inhibace should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Inhibace is taken orally, usually once daily or as directed by the prescriber. Tablets should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule provided by their healthcare professional.

Serious adverse events include angioedema (swelling of the face, lips, tongue, or airway), severe hypotension, acute kidney injury, marked hyperkalemia, and rare cases of liver dysfunction or blood‑cell abnormalities. Prompt medical attention is required if any of these symptoms develop.

Inhibace is contraindicated in patients with a known hypersensitivity to cilazapril or any ACE‑inhibitor, a history of angioedema related to ACE‑inhibitor therapy, and those with severe renal artery stenosis. Caution is also advised for individuals with significant kidney or liver disease, and it should be avoided during pregnancy unless absolutely necessary.